Még nem toboroz
Bacterial Decolonization to Prevent Severe Radiation Dermatitis in Head and Neck Squamous Cell Carcinoma
NCT07888907· Institut Cancerologie de l'Ouest· Forrás
Contact: Yoann POINTREAU, MD
Toboroz
Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test
2025-521045-24-00· 3. fázis· Unicancer· Forrás
Toboroz
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
NCT07333066· 3. fázis· Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD· Forrás
Toboroz
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
NCT07264075· 3. fázis· Groupe Oncologie Radiotherapie Tete et Cou· Forrás
Toboroz
A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
NCT07489495· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT07276399· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC.
2024-516906-47-00· 2/3. fázis· Daiichi Sankyo Inc.· Forrás
Toboroz
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
NCT07211958· 3. fázis· Syndax Pharmaceuticals· Forrás
Toboroz
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
NCT06959108· 2. fázis· Groupe Oncologie Radiotherapie Tete et Cou· Forrás
Toboroz
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154· 2. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· 3. fázis· AstraZeneca· Forrás
Toboroz
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
NCT06757634· 3. fázis· Celcuity Inc· Forrás
Toboroz
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· 3. fázis· BioNTech SE· Forrás
Toboroz
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236· 1/2. fázis· BioNTech SE· Forrás
Toboroz
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
NCT06625970· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485· 3. fázis· Celgene· Forrás
Toboroz
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· 2. fázis· Centre Hospitalier Universitaire De Dijon· Forrás
Toboroz
Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N
NCT06640725· 2. fázis· Groupe Oncologie Radiotherapie Tete et Cou· Forrás
Fut, nem toboroz
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984· 3. fázis· Amgen· Forrás
Toboroz
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
NCT06435429· 3. fázis· Jazz Pharmaceuticals Ireland Limited· Forrás
Toboroz
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
NCT06525220· 3. fázis· Genmab· Forrás
Fut, nem toboroz
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
NCT06365853· 2. fázis· AbbVie· Forrás
Fut, nem toboroz
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
NCT06496178· 3. fázis· Genmab· Forrás
Fut, nem toboroz
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738· 3. fázis· Olema Pharmaceuticals, Inc.· Forrás
Fut, nem toboroz
A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
NCT05653219· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· 3. fázis· Gilead Sciences· Forrás
Fut, nem toboroz
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· 3. fázis· ARCAGY/ GINECO GROUP· Forrás
Toboroz
Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer
NCT05183984· 2. fázis· ARCAGY/ GINECO GROUP· Forrás
Fut, nem toboroz
Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer
NCT05041842· 2. fázis· UNICANCER· Forrás
Fut, nem toboroz
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
NCT04576156· 3. fázis· Geron Corporation· Forrás
Fut, nem toboroz
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the
Metastatic Setting
2024-516653-44-00· 3. fázis· AstraZeneca AB· Forrás
Fut, nem toboroz
Relapse in Previously Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiated by Metformin
NCT04536805· 1/2. fázis· Institut Cancerologie de l'Ouest· Forrás
Fut, nem toboroz
Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)
NCT03795207· 2. fázis· Institut Cancerologie de l'Ouest· Forrás
Toboroz
REal World Data in LYmphoma and Survival in Adults
NCT03869619· Hospices Civils de Lyon· Forrás
Contact: Katell LE DÛ, MD
Fut, nem toboroz
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck
2024-513206-65-00· 3. fázis· Groupe Oncologie Radiotherapie Tete Cou· Forrás
Fut, nem toboroz
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
NCT03223961· 3. fázis· Groupe Francophone des Myelodysplasies· Forrás
Fut, nem toboroz
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC
NCT03395197· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
NCT01957436· 3. fázis· UNICANCER· Forrás
Fut, nem toboroz
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
NCT00005584· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás